Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week before Randomization in the SOCRATES Trial

Stroke

Volumn 49, Issue 7, 2018, Pages 1678-1685

  Wong, K S Lawrence ^a   Amarenco, Pierre ^b   Albers, Gregory W ^c   Denison, Hans ^d   Easton, J Donald ^e   Evans, Scott R ^f   Held, Peter ^d   Himmelmann, Anders ^d   Kasner, Scott E ^g   Knutsson, Mikael ^d   Ladenvall, Per ^d   Minematsu, Kazuo ^h   Molina, Carlos A ⁱ   Wang, Yongjun ^j   Claiborne Johnston, S ^k  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BICHAT HOSPITAL   (France)

^c STANFORD UNIVERSITY   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARVARD UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j CAPITAL MEDICAL UNIVERSITY   (China)

^k UNIVERSITY OF TEXAS AT AUSTIN   (United States)

more..

Author keywords

aspirin; platelet aggregation inhibitors; stroke; ticagrelor; transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; DRUG INTERACTION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; STROKE; TICAGRELOR; TREATMENT OUTCOME;

EID: 85060547870     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.118.020553     Document Type: Article

References (19)

1. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, CHANCE Investigators Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013 369 11 19. doi: 10.1056/NEJMoa1215340
2. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, TIAregistry.org Investigators One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016 374 1533 1542. doi: 10.1056/NEJMoa1412981
3. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, SOCRATES Steering Committee and Investigators Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016 375 35 43. doi: 10.1056/NEJMoa1603060
4. CAST (Chinese Acute Stroke Trial) Collaborative Group CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997 349 1641 1649. doi: 10.1016/S0140-6736(97)04010-5
5. International Stroke Trial Collaborative Group The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997 349 1569 1581. doi: 10.1016/S0140-6736(97)04011-7
6. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014 45 2160 2236. doi: 10.1161/STR.0000000000000024
7. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, CHANCE Investigators Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016 316 70 78. doi: 10.1001/jama.2016.8662
8. Husted S, van Giezen JJ, Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009 27 259 274. doi: 10.1111/j.1755-5922.2009.00096.x
9. Cattaneo M, Schulz R, Nylander S, Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014 63 2503 2509. doi: 10.1016/j.jacc.2014.03.031
10. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Held P, Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. Int J Stroke 2015 10 1304 1308. doi: 10.1111/ijs.12610
11. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG, The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis 2013 36 1 5. doi: 10.1159/000352050
12. Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, SOCRATES Steering Committee and Investigators Risk for major bleeding in patients receiving ticagrelor compared with aspirin after transient ischemic attack or acute ischemic stroke in the SOCRATES study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Circulation 2017 136 907 916. doi: 10.1161/CIRCULATIONAHA.117.028566
13. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z, Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: Time-course analysis of randomised trials. Lancet 2016 388 365 375. doi: 10.1016/S0140-6736(16)30468-8
14. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial. Circulation 2005 111 2233 2240. doi: 10.1161/01.CIR.0000163561.90680.1C
15. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, CLAIR Study Investigators Clopidogrel Plus Aspirin Versus Aspirin Alone for Reducing Embolisation in Patients With Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR study): A randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010 9 489 497. doi: 10.1016/S1474-4422(10)70060-0
16. Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial: rationale and design. Int J Stroke 2013 8 479 483. doi: 10.1111/ijs.12129
17. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B, Antiplatelet regimen for patients with breakthrough strokes while on aspirin. A systematic review and meta-Analysis. Stroke 2017 48 2610 2613. doi: 10.1161/STROKEAHA.117.017895
18. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, SOCRATES Steering Committee and Investigators Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: A subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 2017 16 301 310. doi: 10.1016/S1474-4422(17)30038-8
19. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation 2016 134 861 871. doi: 10.1161/CIRCULATIONAHA.116.024637.